Bariatric surgery can result in profound weight loss and remission of type 2 diabetes. Following meal consumption post-surgery, patients exhibit an exaggerated increase in the circulating levels of the enteroendocrine L-cell peptides peptide YY (PYY) and glucagon-like peptide-1 (GLP-1). We have developed a long-acting PYY Y2 and GLP-1 receptor agonist (GLP-1-Fc-PYY), which exerted potent effects on improving glucose metabolism and body weight loss in diabetic db/db mice and diet-induced obese (DIO) mice. Administration of GLP-1-Fc-PYY to diabetic db/db mice for 28 days normalized HbA1c levels (4.3%) compared to vehicle controls (9.1%), and exceeded that observed with Fc-GLP-1 monotherapy treatment (7.2%). GLP-1-Fc-PYY administration also preserved circulating insulin levels and increased pancreatic insulin content in db/db mice, which was not observed in mice treated with Fc-GLP-1. Administration of GLP-1-Fc-PYY for 21 days in DIO mice resulted in a 28% (p<0.0001) decrease in body weight, whereas vehicle-treated mice gained 13% and Fc-GLP-1-treated mice only exhibited a 13% reduction in body weight. To further characterize the GLP-1-Fc-PYY molecule, DIO GLP-1R knockout (KO) mice were treated for 13 days, and effects on body weight loss were partially attenuated in GLP-1R KO mice (10% BW loss), compared to wild type mice (32% BW loss). Additionally, when GLP-1R KO DIO mice were challenged with an IP glucose bolus following sub-chronic GLP-1-Fc-PYY treatment, the improvement in glucose excursion was lost compared to wild type mice. DIO Y2R KO mice treated for 11 days with GLP-1-Fc-PYY had attenuated BW loss (9%) compared to wild type mice (32%). These data suggest that GLP-1-Fc-PYY is a balanced dual agonist with in vivo activity at both the GLP-1 and Y2 receptors. GLP-1-Fc-PYY therefore represents a PYY/GLP-1 long-acting dual agonist that produces robust bariatric surgery-like weight loss and antidiabetic efficacy in relevant rodent models.


S. Oldham: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca. V.G. Howard: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca. S. Will: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca. D.C. Hornigold: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca. C.J. Rhodes: Employee; Self; AstraZeneca, MedImmune. S. Madalli: None. I. Sermadiras: None. J. Naylor: Employee; Self; MedImmune. Stock/Shareholder; Self; AstraZeneca. C. Rivera: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at